EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)

485 reported adverse events

Drug classes: Endoglycosidase [EPC] Neonatal Fc Receptor Blocker [EPC]

These side effects are most commonly reported by patients taking EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT):

# Side effect Count
0 MYASTHENIA GRAVIS 68
1 FATIGUE 67
2 ASTHENIA 40
3 DRUG INEFFECTIVE 38
4 FALL 37
5 MUSCULAR WEAKNESS 37
6 INJECTION SITE ERYTHEMA 25
7 MYASTHENIA GRAVIS CRISIS 25
8 CONDITION AGGRAVATED 24
9 HEADACHE 24
See all common reactions for EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)

EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PHOTOTHERAPEUTIC KERATECTOMY 1 0.3333
1 LEFT-HANDEDNESS 1 0.2000
2 ACTIVITIES OF DAILY LIVING ASSESSMENT 1 0.0500
3 PROCEDURAL HEADACHE 16 0.0390
4 HEPATIC NEUROENDOCRINE TUMOUR 1 0.0270
5 MYASTHENIA GRAVIS CRISIS 25 0.0169
6 CATHETER SITE SCAR 1 0.0167
7 CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY 22 0.0153
8 OVERWORK 1 0.0128
9 PROCEDURAL DIZZINESS 4 0.0124
See all enriched reactions for EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)